Articles tagged with: Revlimid
News »
FDA Announces Update About Revlimid And Second Cancers – The U.S. Food and Drug Administration (FDA) issued an extensive update last week regarding the risk of developing a second cancer while being treated with Revlimid (lenalidomide). The FDA conducted an analysis that shows that patients newly diagnosed with the blood cancer multiple myeloma who are treated with long-term Revlimid therapy are nearly three times as likely to develop a second cancer than patients not treated with Revlimid. In the update, the FDA says that it continues to recommend that physicians monitor patients being treated with Revlimid for the development of second cancers, and that physicians take into account both the potential benefit of the drug and the risk of second cancers when considering treating a patient with Revlimid. Revlimid is currently approved for the treatment of myelodysplastic syndromes (MDS) patients who are transfusion-dependent and have a deletion in chromosome 5. It also is approved for the treatment of patients with multiple myeloma who have received at least one prior therapy. For more information, please see the full text of the FDA update as well as previous Beacon articles about Revlimid and second cancers.
Onconova Announces Phase 2 Clinical Trial Of Oral Estybon In MDS – Onconova Therapeutics last week announced the start of a Phase 2 clinical trial of its investigational drug Estybon (rigosertib, ON 01910.Na) in MDS. The study will evaluate the effectiveness of the oral formulation of Estybon in reducing the transfusion needs of transfusion-dependent lower-risk MDS patients. Estybon works by inhibiting cell growth and selectively killing cancer cells. The intravenous formulation of Estybon is currently being investigated in a Phase 3 trial for refractory MDS in the U.S. and Europe. For more information about the Phase 2 study, please see the Onconova press release or the clinical trial description.
Living With MDS Conference For Patients And Families – The Aplastic Anemia and MDS International Foundation (AA&MDSIF) will hold a free, one-day conference about living with MDS in Atlanta on May 19. Patients and their families are invited to learn about developments in the diagnosis and treatment of MDS from MDS experts. The program will run from 8:30 a.m. till 5 p.m., and a complimentary breakfast and lunch will be provided. Advance registration is required. For more information or to register, please see the AA&MDSIF website.
Headline, News »
Results from a Phase 1 clinical trial suggest that the combination of Telintra and Revlimid may be effective and safe in lower-risk myelodysplastic syndromes patients.
The study investigators found that the combination of Telintra and Revlimid promoted the growth of new blood cells. In addition, several patients who were previously dependent on red blood cell transfusions became transfusion-independent after therapy.
Based on their findings, the investigators conclude that the combination should be further investigated in clinical trials.
“The determination of the optimal doses for the Telintra/Revlimid combination in this Phase…
Headline, News »
Researchers have recently found that gains in chromosome 8 may be associated with a higher response to Revlimid in myelodysplastic syndromes patients without a deletion in chromosome 5.
The U.S.-based research team also found that newer diagnostic techniques, such as fluorescence in situ hybridization and single nucleotide polymorphism array, moderately improve the detection of deletions in chromosome 5, and significantly improve detection of other chromosomal abnormalities.
Revlimid (lenalidomide) is approved by the U.S. Food and Drug Administration as a treatment for lower-risk myelodysplastic syndromes (MDS) patients who are dependent on blood…
Headline, News »
Preliminary findings from an ongoing Phase 1 trial show that a therapeutic vaccine combined with Revlimid generates a treatment response in some high-risk myelodysplastic syndromes patients.
Furthermore, among patients in the trial who have responded to the combination regimen, an immune system response also was observed.
This suggests that the treatment may be encouraging the body’s immune system to fight the myelodysplastic syndromes, which is what the researchers hoped to achieve with the treatment regimen.
The researchers’ findings were presented during a poster session at the 2011 meeting of the…
Featured, Headline, News »
A retrospective analysis of clinical trials involving the use of Revlimid in lower-risk myelodysplastic syndromes patients shows that that the rate of cancer for Revlimid-treated MDS patients is similar to the rate of cancer in the general public.
The findings were presented at the 2011 American Society of Hematology (ASH) meeting held in December.
The results need to be considered carefully, however, because the analysis compares the rate of second cancers among Revlimid-treated MDS patients in clinical trials with the rate of cancer in the general public.
A more relevant…